U.S. National Quantum Initiative Act Signed and Delivered - What's Next?
In case you missed it, the U.S National Quantum Initiative Act was signed into law by President Donald Trump on December 21 just before end-of-year holidays.
How Do We Redirect Scientific Investigation?
Is it possible to direct scientific research? Scientists working in the private sector are directed by their corporate funders.
Trump signs legislation to boost quantum computing research with $1.2 billion
President Donald Trump on Friday signed legislation ramping up quantum computing research and development. The National Quantum Initiative Act (H.R.
Senate passes plan to invest $1.2 billion in quantum research
The Senate cleared the way for the president to approve implementation of a 10-year plan to accelerate quantum computing research and development. The National Quantum Initiative Act, introduced by Sens.
China Expands Research Funding, Luring U.S. Scientists And Students
In the past decade or so, China has been expanding its commitment to scientific research, and it shows. Chinese researchers now produce more scientific publications than U.S.
Higher Ed R&D by state, 2008-2017
Higher education R&D expenditures (HERD) grew by 38.9 percent from 2008 to 2017, an increase of more than $21 billion, according to an SSTI analysis of recently released data from the National Science Foundation’s National Center for Science and Engineering Statistics.
We're No. 25: Why the US Must Increase Its Tax Incentives for R&D
A recent report by Ernst & Young documents continued efforts by countries to enact additional tax incentives to reward companies for research and development.
Business R&D Intensity by State (2011-2016)
Since 2011, more than half of the nation's new investment in business research and development has come from California companies, and more than three-quarters has come from the top five states, according to an SSTI analysis of recently released NSF data.
DowDuPont CEO says split will generate nearly $1 billion in research funding
"The beauty of redoing the portfolio -- and I'll use DuPont as the example -- [is] we're going to spend almost $1 billion on R&D per year, so it's at a rate that's very healthy compared to the competitive peer set," Breen told Jim Cramer in an interview.